http://orcid.org/0000-0003-4665-6665
References
- Al-Sha’er, M. A., & Taha, M. O. (2018). Ligand-based modeling of Akt3 lead to potent dual Akt1/Akt3 inhibitor. Journal of Molecular Graphics and Modelling, 83, 153–166. doi:10.1016/j.jmgm.2018.02.001
- Carnero, A. (2010). The PKB/AKT pathway in cancer. Current Pharmaceutical Design, 16(1), 34–44. doi:10.2174/138161210789941865
- Chuang, C.-H., Cheng, T.-C., Leu, Y.-L., Chuang, K.-H., Tzou, S.-C., & Chen, C.-S. (2015). Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents. International Journal of Molecular Sciences, 16(2), 3202–3212. doi:10.3390/ijms16023202
- Dong, X., Zhou, X., Jing, H., Chen, J., Liu, T., Yang, B., … Hu, Y. (2011). Pharmacophore identification, virtual screening and biological evaluation of prenylated flavonoids derivatives as PKB/Akt1 inhibitors. European Journal of Medicinal Chemistry, 46(12), 5949–5958. doi:10.1016/j.ejmech.2011.10.006
- Fratev, F., Miranda-Arango, M., Lopez, A. B., Padilla, E., & Sirimulla, S. (2019). Discovery of GlyT2 inhibitors using structure-based pharmacophore screening and selectivity studies by FEP + calculations. ACS Medicinal Chemistry Letters, 10(6), 904–910. doi:10.1021/acsmedchemlett.9b00003
- Fratev, F., Rivera, M., & Sirimulla, S. (2017, October 29 – November 1). Efficient structure-based protocol for lead identification. ACS SWRM Conference, Lubbock, TX, USA. doi:10.13140/RG.2.2.21299.78882
- Fratev, F., & Sirimulla, S. (2019). An improved free energy perturbation FEP + sampling protocol for flexible ligand-binding domains. Scientific Reports, 9(1), 16829. doi:10.1038/s41598-019-53133-1
- Freeman-Cook, K. D., Autry, C., Borzillo, G., Gordon, D., Barbacci-Tobin, E., Bernardo, V., … Morris, J. (2010). Design of selective, ATP-competitive inhibitors of Akt. Journal of Medicinal Chemistry, 53(12), 4615–4622. doi:10.1021/jm1003842
- Lema, C., Varela-Ramirez, A., & Aguilera, R. J. (2011). Differential nuclear staining assay for high-throughput screening to identify cytotoxic compounds. Journal of Cellular Biochemistry, 1(2011): 1–14.
- Lopes-Coelho, F., Nunes, C., Gouveia-Fernandes, S., Rosas, R., Silva, F., Gameiro, P., … Serpa, J. (2017). Monocarboxylate transporter 1 (MCT1), a tool to stratify acute myeloid leukemia (AML) patients and a vehicle to kill cancer cells. Oncotarget, 8(47), 82803–82823. doi:10.18632/oncotarget.20294
- Medina-Franco, J. L., Giulianotti, M. A., Yu, Y., Shen, L., Yao, L., & Singh, N. (2009). Discovery of a novel protein kinase B inhibitor by structure-based virtual screening. Bioorganic & Medicinal Chemistry Letters, 19, 4634–4638. doi:10.1016/j.bmcl.2009.06.078
- Merchant, A. A., Jorapur, A., McManus, A., Liu, R., Krasnoperov, V., Chaudhry, P., … Gill, P. S. (2017). EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Advances, 20, 1635–1644. doi:10.1182/bloodadvances.2017005694
- Mu, X., Zhao, T., Xu, C., Shi, W., Geng, B., Shen, J., … You, Q. (2017). Oncometabolite succinate promotes angiogenesis by upregulating VEGF expression through GPR91-mediated STAT3 and ERK activation. Oncotarget, 8(8), 13174–13185. doi:10.18632/oncotarget.14485
- Peach, M. L., & Nicklaus, M. C. (2009). Combining docking with pharmacophore filtering for improved virtual screening. Journal of Cheminformatics, 1(1), 6. doi:10.1186/1758-2946-1-6
- Severson, A. F., & Meyer, B. J. (2014). Divergent kleisin subunits of cohesin specify mechanisms to tether and release meiotic chromosomes. eLife, 3. doi:10.7554/eLife.03467
- Siegel, R., Ma, J., Zou, Z., Jemal, A. (2014). Cancer statistics, 2014. CA: A Cancer Journal for Clinicians, 64, 9–29. doi:10.3322/caac.21208